Royal Bank of Canada’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,358
| Closed | -$4K | – | 7965 |
|
|
2023
Q1 | $4K | Sell |
2,358
-3,494
| -60% | -$4.33K | ﹤0.01% | 6661 |
|
|
2022
Q4 | $6K | Buy |
5,852
+5,339
| +1,041% | +$7.6K | ﹤0.01% | 6710 |
|
|
2022
Q3 | $1K | Buy |
513
+276
| +116% | +$977 | ﹤0.01% | 7358 |
|
|
2022
Q2 | $1K | Sell |
237
-2,088
| -90% | -$10.2K | ﹤0.01% | 7276 |
|
|
2022
Q1 | $16K | Sell |
2,325
-4,540
| -66% | -$32.4K | ﹤0.01% | 6740 |
|
|
2021
Q4 | $58K | Buy |
6,865
+2,332
| +51% | +$19.2K | ﹤0.01% | 6297 |
|
|
2021
Q3 | $34K | Buy |
4,533
+1,975
| +77% | +$12.2K | ﹤0.01% | 6391 |
|
|
2021
Q2 | $17K | Buy |
2,558
+275
| +12% | +$2.29K | ﹤0.01% | 6661 |
|
|
2021
Q1 | $23K | Buy |
2,283
+1,304
| +133% | +$14.3K | ﹤0.01% | 6352 |
|
|
2020
Q4 | $7K | Buy |
979
+679
| +226% | +$5.29K | ﹤0.01% | 6556 |
|
|
2020
Q3 | $2K | Hold |
300
| – | – | ﹤0.01% | 6356 |
|
|
2020
Q2 | $2K | Sell |
300
-1,849
| -86% | -$9.97K | ﹤0.01% | 6337 |
|
|
2020
Q1 | $10K | Buy |
2,149
+805
| +60% | +$4.63K | ﹤0.01% | 5841 |
|
|
2019
Q4 | $12K | Buy |
1,344
+1,044
| +348% | +$5.64K | ﹤0.01% | 6087 |
|
|
2019
Q3 | $1K | Hold |
300
| – | – | ﹤0.01% | 6567 |
|
|
2019
Q2 | $1K | Hold |
300
| – | – | ﹤0.01% | 6768 |
|
|
2019
Q1 | $2K | Hold |
300
| – | – | ﹤0.01% | 6570 |
|
|
2018
Q4 | $1K | Sell |
300
-316
| -51% | -$1.48K | ﹤0.01% | 6634 |
|
|
2018
Q3 | $4K | Sell |
616
-205
| -25% | -$1.52K | ﹤0.01% | 6363 |
|
|
2018
Q2 | $6K | Sell |
821
-979
| -54% | -$14.1K | ﹤0.01% | 6005 |
|
|
2018
Q1 | $40K | Buy |
1,800
+1,453
| +419% | +$32.2K | ﹤0.01% | 5157 |
|
|
2017
Q4 | $5K | Sell |
347
-990
| -74% | -$14.6K | ﹤0.01% | 6087 |
|
|
2017
Q3 | $21K | Buy |
1,337
+1,257
| +1,571% | +$17.8K | ﹤0.01% | 5935 |
|
|
2017
Q2 | $1K | Sell |
80
-320
| -80% | -$6.85K | ﹤0.01% | 6458 |
|
|
2017
Q1 | $9K | Buy |
+400
| New | +$8.47K | ﹤0.01% | 6024 |
|
Other funds holding JNCE
Royal Bank of Canada's JNCE Position: Q2 2023 in Review
Royal Bank of Canada sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 2,358 shares — an estimated $4K sold.
Royal Bank of Canada first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $58K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Royal Bank of Canada reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Royal Bank of Canada sold 2,358 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4K.
- Royal Bank of Canada first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Royal Bank of Canada's Jounce Therapeutics, Inc. Common Stock position peaked at $58K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.